Nova Patents
IS7530A

Hepatitis c virus inhibitors

Abstract

Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R 1 , R 2 , R 3 , R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Term

Term ended

Projected expiry passed 16 November 2024, 1.9 years ago.

  1. Priority
  2. Filed
  3. Projected expiry
  4. Today

49 claims: 35 independent, 14 dependent

  1. 1
    Einkaleyfisumsókn nr. 7530/2004 (PCT/US03/15755) Patent Application No. 7530/2004 (PCT / US03 / 15755) Application date:16.11.2004 Prior rights from: 20.05.2002 Umsóknardagur: 16.11.2004 Forgangsréttur frá: 20.05.2002 Applicant: Bristol-Myers Squibb Company, US Umsækjandi: Bristol-Myers Squibb Company, Bandarikjunum Inventors: WANG, Xiangdong, Alan;Uppfinningarmenn: WANG, Xiangdong, Alan;SUN, Li-Quang;SIT, Sing-Yuen;SIN, New;SUN, Li-Quang;SIT, Sing-Yuen;SIN, Ny;SCOLA, Paul, Michael;HEWAWASAM, Piyasena;GOOD, Andrew, Charles;CHEN, Yan;CAMPELL, Jeffrey, Allen;Bandarikjunum SCOLA, Paul, Michael;HEWAWASAM, Piyasena;GOOD, Andrew, Charles;CHEN, Yan;CAMPELL, Jeffrey, Allen;U.S. Agent: Kjartan Ragnars, Supreme Court Attorney. Umboðsmaður: Kjartan Ragnars, hrl. Icelandic translation of patent no. 1-49, bis. 1-11 íslensk þýðing einkaleyfiskrafna nr. 1-49, bis. 1-11 Hepatitis C virus inhibitors Lifrarbólgu C-veirutálmar CLAIMS Einkaleyfiskröfur 1. Efnasamband með formúluna A compound of the formula X-R 'where: X—R' þar sem: (a) R y is C j.8 alkyl, C3_7 cycloalkyl, or C4-10 alkylcycloalkyl;(a) Rj er Cj.8 alkýl, C3_7 sýklóalkýl, eða C4.10 alkýlsýklóalkýl;(b) m er 1 eða 2;(b) m is 1 or 2;ί ft 02., ON (c) n er 1 eða 2;ί ft 02., ON (c) n is 1 or 2;(d) R2 er H, C i .6 alkýl, C2_6 alkenýl eða C3.7 sýklóalkýl, hver skiptitengjanlegur með halogen;(d) R2 is H, C 1-6 alkyl, C2_6 alkenyl or C3.7 cycloalkyl, each optionally substituted with halogen;(e) R3 er Ci_g alkýl skiptitengjanlegur með haló, cýanó, amínó, Ci.ódíalkýlamínó, Cö-io arýl, C7.i4alkýlarýl, Ci_6alkoxý, karboxý, hýdroxý, arýloxý, C7.14alkýlarýloxý, (e) R3 is C1-6 alkyl optionally substituted with halo, cyano, amino, C1-4 dialkylamino, C1-10 aryl, C7being detected4alkylaryl, C1_6alkoxy, carboxy, hydroxy, aryloxy, C7.14alkylaryloxy, C2.6 alkyl ester, C 1-6 alkylaryl ester;C3being detected2alkenyl, C2.6 alkýlestra, Cg.isalkýlarýlestra;C3.i2alkenýl, C3.7 cycloalkyl, or C4.] 0 alkylcycloalkyl, wherein cycloalkyl or alkylcycloalkyl is optionally substituted with hydroxy, C3.7 sýklóalkýl, eða C4.]0 alkýlsýklóalkýl, þar sem sýklóalkýl eða alkýlsýklóalkýl eru skiptitengjanlegir með hýdroxý, C 1-6 alkyl, C2.6alkenyl or C1.6alkoxy;or R3 together with the carbon atom to which it is attached, C forms3.7 cycloalkyl group optionally substituted with C2_6 alkenyl;Cj.6alkýl, C2.6alkenýl eða Ci.6alkoxý;eða R3 saman með kolefnisatóminu, sem hann er tengdur við, myndar C3.7 sýklóalkýl hóp skiptitengjanlegur með C2_6 alkenýl;(f) Y er H, fenýl skiptitengdur með nítró, pýridýl skiptitengdur með nítró, eða Ci.6 alkýl skiptitengjanlegur með cýanó, OH eða C3.7 sýklóalkýl;að því gefnu, að sé R| eða R5 H, er YH;(f) Y is H, phenyl substituted with nitro, pyridyl substituted with nitro, or C1.6 alkyl optionally substituted with cyano, OH or C3.7 cycloalkyl;assuming that R is or R5 is H, is YH;(g) B er H, C,.6 alkýl, R4-(C=O)-, RACK))-, (g) B is H, C ,.6 alkyl, R4- (C = O) -, RACK)) -, R4-N (R5) -C (= O) -, R 4 -N (R5) -C (= S) -, R4SO2-, or R4-N (R5) -SO2-;R4-N(R5)-C(=O)-, R4-N(R5)-C(=S)-, R4SO2-, eða R4-N(R5)-SO2-;(h) R & lt;1 & gt;is (i) C 1-4 alkyl optionally substituted with phenyl, carboxy,6 alkanoyl, 1-3 halogen, hydroxy, -OC (O) C 1-6 alkyl, C 1-6 alkyl.6alkoxy, amino optionally substituted with C1-6 alkyl, amido, or (lower alkyl) amido;(ii) C3.7 cycloalkyl, (h) Rzi er (i) Cuo alkýl skiptitengjanlegur með fenýl, karboxýl, Cj_6 alkanóýl, 1-3 halógen, hýdroxý, -OC(O)Ci.6alkýl, Ci.6alkoxý, amínó skiptitengjanlegur með Ci.ðalkýl, amídó, eða (smærri alkýl) amídó;(ii) C3.7 sýklóalkýl, C3.7 cycloalkoxy, or C4-10 alkylcycloalkyl, each optionally substituted with hydroxy, carboxy, (C1-6 alkyl)6alkoxy) carbonyl, amino optionally substituted with C1-6 alkyl, amido, or (lower alkyl) amido;(iii) C6.j0 aryl or C7C1-6 arylalkyl, each optionally substituted with C1-66 alkyl, halogen, nitro, hydroxy, amido, (lower alkyl) amido, or amino optionally substituted with Cl6 alkyl;(iv) It;(v) bicyclo (III) pentane;or (vi) -C (O) OC 1-6 alkyl, C 1-6 alkenyl or C2.6 alkynyl;C3.7 sýklóalkoxý, eða C4.10 alkýlsýklóalkýl, hver skiptitengjanlegur með hýdroxý, karboxýl, (Ci.6alkoxý)karbónýl, amínó skiptitengjanlegur með Ci_6 alkýl, amídó, eða (smærri alkýl)amídó;(iii) C6.j0 arýl eða C7_i6 arýlalkýl, hver skiptitengjanlegur með Ci_6 alkýl, halógen, nítró, hýdroxý, amídó, (smærri alkýl) amídó, eða amínó skiptitengjanlegur með Cj.6 alkýl;(iv) Het;(v) bísýkló(l.l.l)pentan;eða (vi) -C(O)OCi.6alkýl, CAalkenýl eða C2.6 alkýnýl;(i) R5 er H;Ci.6alkýl skiptitengjanlegur með 1-3 halógenum;eða C].6alkoxý, að því gefnu, að R4 sé Cmoalkýl;(i) R5 is H;C.6alkyl optionally substituted with 1-3 halogens;or C].6alkoxy, provided that R 4 is C 1-4 alkyl;(j) X er O, S, SO, SO2, OCH2, CH2O eða NH;(j) X is O, S, SO, SO2, AND2, CH2O or NH;(k) R 'is Het;or C6.10 aryl or C7.14 alkylaryl, optionally substituted with Ra;and (1) Ra is Cj.6 alkyl, C3.7 cycloalkyl, C1_6 alkoxy, (k) R' er Het;eða C6.10 arýl eða C7.14 alkýlarýl, skiptitengjanlegur með Ra;og (l) Ra er Cj.6 alkýl, C3.7 sýklóalkýl, Ci_6 alkoxý, C3.7 cycloalkoxy, halo-C 1-6 alkyl, CF3, mono- or di-halo-alkoxy, cyano, halo, thioalkyl, hydroxy, alkanoyl, NO2, SH, amino, C1-6alkylamino, di (C1-4alkyl)6(C1-6) alkylamino, di (C1-6) alkylamide, carboxy, (C1-6 carboxylic acid, C3.7 sýklóalkoxý, haló-Cj.ð alkýl, CF3, mónó- eða dí-haló-CAalkoxý, cýanó, haló, þíóalkýl, hýdroxý, alkanóýl, NO2, SH, amínó, C].6alkýlamínó, dí(Ci_6)alkýlamínó, dí(C].6)alkýlamíð, karboxýl, (Cpðjkarboxýestra, C1-6 alkylsulfone, C1.6 alkylsulphonamide, di (C1-6) alkyl (alkoxy) amine, C1-10 aryl, Ci_6 alkýlsúlfon, C1.6 alkýlsúlfonamíð, dí(Ci.6)alkýl(alkoxý)amín, Cð-io arýl, C744 alkýlarýl, eða 5-7 staka mónósýklískur heteróhringur með þeim fyrirvara, að X-R' er ekki eða lyfjafrædilega tækt salt, lausnarsamband eda forlyf þess. C744-alkylaryl, or 5-7 membered monocyclic heterocycle with the proviso that XR is not or pharmacologically acceptable salt, solvate of its prodrug.
  2. 4
    Efnasambandið samkvæmt einkaleyfiskröfu nr. 3, þar sem R? er C2-6 alkenýl. 4. The compound of claim no. 3, wherein R? is C2-6 alkenyl.
  3. 6
    Efnasambandið samkvæmt einkaleyfiskröfu nr. 5, þar sem R3 er C1.8 alkýl skiptitengjanlegur með C].6 alkoxý;eða C3.7 sýklóalkýl. 6. The compound of claim no. 5, wherein R3 is C1-8 alkyl optionally substituted by C1.6 alkoxy;or C3.7 cycloalkyl.
  4. 8
    Efnasambandið samkvæmt einkaleyfiskröfu nr. 1, þar sem B er H, Cb6 alkyl, MOO)-, R^CO)-, R4-N(R5)-C(=O)-, R4-N(R5)-C(=S)-, R4SO2-, eða R4-N(R5)-SO2-. 8. The compound of claim no. 1, wherein B is H, Cb6 alkyl, MOO) -, R 4 CO) -, R 4 -N (R5) -C (= O) -, R 4 -N (R5) -C (= S) -, R4SO2-, or R4-N (R5) -SO2-.
  5. 9
    Efnasambandið samkvæmt einkaleyfískröíu nr. 8, þar sem B er R4-(C=O)-, R4O(C=O)-, eða R4-N(R5)-C(=O)-. 9. The compound according to patent no. 8, wherein B is R4- (C = O) -, R4O (C = O) -, or R4-N (R5) -C (= O) -.
  6. 10
    Efnasambandið samkvæmt einkaleyfiskröfu nr. 9, þar sem B er R4O(C=O)- og R4 er Ci_6alkýl. 10. The compound of claim no. 9, wherein B is R 4 O (C = O) - and R 4 is C 16alkyl.
  7. 12
    A compound according to claim no. 11, wherein R 4 is (i) C 1-10 alkyl optionally substituted with 1-3 halogen or C6alkoxy;or (ii) C3-7 cycloalkyl or C4.10 alkylcycloalkyl. 12. Efnasambandid samkvæmt einkaleyfi skröfu nr. 11, þar sem R4 er (i) Cmo alkýl skiptitengjanlegur með 1-3 halógen eða Cj.6alkoxý;eða (ii) C3.7 sýklóalkýl eða C4.10 alkýlsýklóalkýl.
  8. 15
    Efnasambandid samkvæmt einkaleyfiskröfu nr. 1, þar sem X er O edaNH. A compound according to claim no. 1, wherein X is 0 edaNH.
  9. 17
    A compound according to claim no. 16, wherein R 1 is Het. 17. Efnasambandid samkvæmt einkaleyfiskröfu nr. 16, þar sem R' er Het.
  10. 20
    Efnasambandið samkvæmt einkaleyfiskrofu nr. 1, þar sem Ra er Ci.6 alkýl, C3.7 sýklóalkýl, C].6alkoxý, haló-Cj_6 alkýl, haló, amínó, Cgarýl, eða 5-7 staka einhringja heteróhringur. 20. The compound according to claim no. 1, wherein Ra is Ci.6 alkyl, C3.7 cycloalkyl, C].6alkoxy, halo-C6 alkyl, halo, amino, Caryl, or 5-7 membered monocyclic heterocycle.
  11. 21
    A compound of the formula 21. Efnasamband með formúluna X-Ff where:X-Ff þar sem: (a) (b) (c) (<*) (e) (f) (g) (a) (b) (c) (<*) (e) (f) (g) Ri er C3_7 sýklóalkýl;Ri is C3Cycloalkyl;R2 er Ci.6 alkýl, C2_6 alkenýl eða C3.7 sýklóalkýl;R2 is Ci.6 alkyl, C2_6 alkenyl or C3.7 cycloalkyl;R3 er Ci_g alkýl skiptitengjanlegur með C6arýl, Cj.6alkoxý, karboxý, hýdroxý, arýloxý, C7.i4alkýlarýloxý, R3 is C1-6 alkyl optionally substituted by C6aryl, C6alkoxy, carboxy, hydroxy, aryloxy, C7.i4alkýlarýloxý, C2-6 alkyl ester, C8_i5 alkylarylester;C3being detected2alkenyl, C2-6 alkýlestra, C8_i5 alkýlarýlestra;C3.i2alkenýl, C3.7 cycloalkyl, or C4C1-6 alkylcycloalkyl;C3.7 sýklóalkýl, eða C4_io alkýlsýklóalkýl;Y er H;Y is H;B er H, C,_6 alkýl, MCO)-, RiO(C=O)-, B is H, C, _6 alkyl, MCO) -, R10 (C = O) -, R4-N (R5) -C (= O) -, R4-N (R5) -C (= S) -, R4SO2-, or R4-N (R5) -SO2-;R4-N(R5)-C(=O)-, R4-N(R5)-C(=S)-, R4SO2-, eða R4-N(R5)-SO2-;R 4 is (i) C 1-10 alkyl optionally substituted with phenyl, carboxyl, C 1.6alkanoyl, 1-3 halogen, hydroxy, C1-6 alkyl.6alkoxy;(Ii) R4 er (i) Cmo alkýl skiptitengjanlegur með fenýl, karboxýl, C].6alkanóýl, 1-3 halógen, hýdroxý, Ci.6alkoxý;(ii) C3-7 cycloalkyl, C3-7 cycloalkoxy, or C4-10 alkylcycloalkyl;or (iii) C6aryl or C7being detected6 arylalkyl, each optionally substituted with C 1-6 alkyl or halogen;C3.7 sýklóalkýl, C3.7 sýklóalkoxý, eða C4.10 alkýlsýklóalkýl;eða (iii) C6_io arýl eða C7.i6 arýlalkýl, er hver skiptitengjanlegur með Cj.6 alkýl eða halógen;R5 er H eða Ci.6 alkýl skiptitengjanlegur með 1-3 R5 is H or Ci.6 alkyl optionally substituted with 1-3 A :J 1 a A., IK halógenum;A: J 1 a A., I halogen;(h) XerOdaNH;(h) XerOedaNH;(i) R is there Het;eda c6-10 aryl optionally substituted with Ra;and (j) Ra is C 1-6 alkyl, C3.7 cycloalkyl, C1,6 alkoxy, haloalkyl, halo, amino, C6aryl, or 5-7 membered monocyclic heterocycle;(i) R' er Het;eda C6-io arýl skiptitengjanlegur med Ra;og (j) Ra er Ci.6alkýl, C3.7 sýklóalkýl, Ci,6 alkoxý, hald-CAalkýl, haló, amínó, C6arýl, eða 5-7 staka einhringja heteróhringur;með þeim fyrirvara, að Xa-R' er ekki eða lyfjafræðilega tækt salt, lausnarsamband eða forlyf þess. with the proviso that Xa-R 'is not or pharmaceutically acceptable salt, solvate or prodrug thereof.
  12. 24
    A compound according to claim no. 22, wherein the heterocycle is substituted with at least one 24. Efnasambandid samkvæmt einkaleyfiskröfu nr. 22, þar sem heteróhringurinn er skiptitengdur med ad minnsta kosti einum C 1-6 alkyl, C 1-6 alkoxy, halo, Caryl, and 5-7 membered monocyclic ring ring. Cj_6 alkýl, C[.6alkoxý, haló, Cóarýl, og 5-7 staka einhringja heterdhring.
  13. 25
    Efnasambandid samkvaemt einkaleyfiskröfii nr. 21, þar sem R' er tvihringja heterdhringur med 1 nituratdm og skiptitengdur med metoxý og ad minnsta kosti einum Cfy aryl og 5-7 staka einhringja heterdhring. A compound according to claim no. 21, wherein R & apos;is a cyclic ring containing 1 niturate and substituted with methoxy and at least one C6 aryl and 5-7 membered monocyclic ring cycles.
  14. 26
    A compound according to patent no. 21, wherein R 'is 26. Efnasambandid samkvæmt einkaleyfískröíu nr. 21, þar sem R' er Η Π'Λ 05 einhringja heteróhringur. Η Π'Λ 05 single-ring heterocycle.
  15. 28
    Efnasambandið samkvæmt einkaleyfiskröfu nr. 26, þar sem heteróhringurinn er skiptitengdur með að minnsta kosti einum Ci_6 alkýl, Ci_6alkoxý, haló, Cð-io arýl, C7.14 alkýlarýl, eða 5-7 staka einhringja heteróhring. 28. The compound of claim no. 26, wherein the heterocycle is substituted with at least one C1-6 alkyl, C1-66alkoxy, halo, C10-10 aryl, C7-14 alkylaryl, or 5-7 membered monocyclic heterocycle.
  16. 29
    Efnasambandið samkvæmt einkaleyfiskröfu nr. 21, þar sem R’ er einhringja heteróhringur með 1 eða 2 nituratóm og skiptitengdur með metoxý og að minnsta kosti einum C6 arýl og 5-7 staka einhringja heteróhring. 29. The compound of claim no. 21, wherein R 'is a monocyclic heterocycle having 1 or 2 nitrogen atom and substituted with methoxy and at least one C6 aryl and a 5-7 membered monocyclic heterocycle.
  17. 30
    Efnasamband með formúluna þar sem:A compound of the formula wherein: (a) (b) (c) (a) (b) (c) Ri er C3.7 sýklóalkýl;R2 er C2_6 alkenýl;Ri is C3.7 cycloalkyl;R2 is C2Alkenyl;R3 erCpg alkýl;R3 isC1-4 alkyl;1 's 3 u 1 ft 02. iB (d) Y is H;1’ S 3 U 1 ft 02. ÍB (d) Y er H;(e) B er 1^0(0=0)-, eða R4-N(R5)-C(=O)-;(e) B is 1 O (O = O) -, or R 4 -N (R5) -C (= O) -;(f) R4ERCl.10alkyl;(f) R4erCl.10alkýl;(g) R5 er H;(g) R5 is H;(h) R 'is a bicyclic heterocycle optionally substituted by Ra;and (i) Ra is C1_6alkyl, C6 alkoxy, halo, C6 aryl, or 5-7 membered monocyclic heterocycle;with the proviso that OR 'is not or pharmaceutically acceptable salt, solvate of its prodrug. (h) R' er tvihringja heteróhringur skiptitengjanlegur með Ra;og (i) Ra er Ci_6alkýl, Cj.6 alkoxý, haló, Cg arýl, eða 5-7 staka einhringja heteróhringur;með þeim fyrirvara, að O-R' er ekki eða lyfjafræðilega tækt salt, lausnarsamband eda forlyf þess.
  18. 31
    A compound according to claim no. Wherein R 1 is cyclopropyl or cyclobutyl. 31. Efnasambandid samkvæmt einkaleyfiskröíu nr. 30, þar sem Rj er sýklóprópýl eða sýklóbútýl.
  19. 32
    A compound according to claim no. 30, wherein R2 is vinyl. 32. Efnasambandid samkvæmt einkaleyfiskröfu nr. 30, þar sem R2 er vínýl.
  20. 33
    A compound according to claim no. 30, wherein R3 is t-butyl. 33. Efnasambandid samkvæmt einkaleyfiskröíu nr. 30, þar sem R3 er t-bútýl.
  21. 35
    Efnasambandid samkvæmt einkaleyfiskröfu nr. 30, þar sem R' er quínólín eda ísóquínólín skiptitengjanlegur med Ra. A compound according to claim no. 30, wherein R 'is quinoline and isoquinoline optionally substituted with Ra. ¥ i A Ö/ ¥ in a z /
  22. 36
    A compound according to claim no. Wherein R 1 is cyclopropyl, R2 is vinyl, R3 is t-butyl, R4 is t-butyl, and R 'is isoquinoline substituted with Ra. 36. Efnasambandid samkvaemt einkaleyfiskrofii nr. 30, þar sem Rj er sýklóprópýl, R2 er vínýl, R3 er t-bútýl, R4 er t-bútýl, og R' er ísóquínólín skiptitengdur med Ra.
  23. 37
    A compound according to claim no. 36, wherein Ra is Cj.6 alkoxy. 37. Efnasambandid samkvaemt einkaleyfiskrofii nr. 36, þar sem Ra er Cj.6 alkoxy.
  24. 38
    A compound according to claim no. 37, wherein Ra also contains at least one cycloalkyl or 5-7 membered monocyclic heterocycle. 38. Efnasambandid samkvaemt einkaleyfiskrofii nr. 37, þar sem Ra inniheldur jafnframt ad minnsta kosti einn Cðarýl eda 5-7 staka einhringja heteróhring.
  25. 39
    A treatment for treating HCV infection in a patient, which comprises administering to the patient a therapeutically effective amount of a compound according to claim no. A pharmaceutically acceptable salt, solvate of a prodrug thereof. 39. Adferd vid ad medhöndla HCV-sýkingu í sjúklingi, sem felur í sér ad gefa sjúklingnum medferdarlega virkt magn Efnasambands samkvaemt einkaleyfiskröfu nr. 1 eda lyfjafraedilega tækt salt, lausnarsamband eda forlyf þess.
  26. 40
    Adaptation of HCV NS3 protease inhibitor, which comprises administering to a patient in need thereof a therapeutically effective amount of a compound according to patent specification no. A pharmaceutically acceptable salt, solvate of a prodrug thereof. 40. Adferd vid ad tálma HCV NS3-próteasa, sem felur í sér ad gefa sjúklingi, sem þess þarfnast, medferdarlega virkt magn Efnasambands samkvaemt einkaleyfiskrofii nr. 1 eda lyfjafraedilega tækt salt, lausnarsamband eda forlyf þess.
  27. 41
    A composition comprising a compound according to claim no. A pharmaceutically acceptable salt, solvate of a prodrug thereof and a likelihood of a suitable carrier. 41. Samsetning, sem hefur ad geyma Efnasambandid samkvaemt einkaleyfiskrofii nr. 1 eda lyfjafrædilega tækt salt, lausnarsamband eda forlyf þess og lyljafrædilega tækt burdarefni.
  28. 42
    Samsetningin samkvaemt einkaleyfiskrofii nr. 41, sem jafnframt hefur ad geyma vidbótarónæmisstillandi virkt efni. 42. The composition according to patent no. 41, which also contains additional immunosuppressive active substances. / + - "ί d 1 6, ÖZ. Öl / + -"ί d 1 6., ÖZ. Öli
  29. 43
    Samsetningin samkvaemt einkaleyfiskröfu nr. 42, þar sem viðbótar-ónæmisstillandi virka efnið er valid úr hópnum, sem samanstendur af α-, β-, og δ-interferónum. 43. The composition according to patent claim no. 42, wherein the additional immunosuppressant active substance is valid from the group consisting of α-, β-, and δ-interferons.
  30. 44
    Samsetningin samkvaemt einkaleyfiskröfu nr. 41, sem jafnframt hefiir að geyma veiruhamlandi efni. 44. The composition according to patent claim no. 41, which also has to contain antiviral substances.
  31. 45
    Samsetningin samkvaemt einkaleyfiskröfu nr. 44, þar sem veiruhamlandi efnið er valid úr hópnum, sem samanstendur af ríbavíríni og amantadini. 45. The composition according to patent claim no. 44, wherein the antiviral agent is valid from the group consisting of ribavirin and amantadine.
  32. 46
    Samsetningin samkvaemt einkaleyfiskröfu nr. 41, sem jafhffamt hefur ad geyma tálma HCV-próteasa annan en Efnasambandid samkvaemt einkaleyfiskröfu nr. 1. 46. ​​The composition according to patent claim no. 41, which also contains inhibitors of HCV protease other than Compound according to claim no. 1.
  33. 47
    Samsetningin samkvaemt einkaleyfiskröfu nr. 46, sem jafnframt hefur ad geyma tálmamark í lífsferli HCV, sem er annad en HCV NS3-próteasi. 47. The composition according to patent claim no. 46, which also has a barrier to HCV's HCV, which is a HCV NS3 protease.
  34. 48
    Samsetningin samkvaemt einkaleyflskröfu nr. 47, þar sem annad markid er valid úr hopnum, sem samanstendur af helícasa, pólýmerasa, metallópróteasa og blöndum þeirra. 48. The composition according to patent claim no. 47, wherein the second marker is valid from the hop consisting of helicase, polymerase, metalloprotease and their mixtures.
  35. 49
    Notkun samsetningarinnar samkvaemt einkaleyfiskröfu nr. 41 til ad framleida lyf til ad medhöndla lifrarbólgu C-veirusýkingu í sjúklingi. 49. Use of the composition according to patent claim no. 41 for a prodrug for the treatment of hepatitis C virus in a patient.
Independent claims35